

Distribution of type 2 diabetes mellitus in chronic hepatitis-C patient; A cross-sectional study conducted in Khyber Teaching Hospital and Khushal Medical Center Peshawar

Bughdad Khan¹, Waqar Ahmad², Fahad Naim³, Nizamuddin⁴, Husnain Qadir⁵ and Samiullah⁶
^{1,2,3} Department of Medicine, Khyber Teaching Hospital Peshawar, ^{4,5}Department of Pharmacology, Khyber Medical College Peshawar ⁶Khushal Medical Center Peshawar

ABSTRACT

Background: Prevalence of Hepatitis C virus infections (HCV) and Diabetes Mellitus (DM) is escalating and is associated with increased morbidity and mortality. Patient with HCV are more prone to develop DM and this study aims to determine the distribution of DM in HCV patients. **Methods:** This descriptive cross sectional enrolled 160 HCV patients from 27th October 2020 till 26th April 2021 at Medicine Unit, Khyber Teaching Hospital (KTH) Peshawar and Khushal Medical Center (KMC) Peshawar. After ethical approval from KMC, the enrolled HCV patients were screened for DM. After detailed interview, blood samples were collected and subsequently processed for glycated hemoglobin A1C (HbA1C). The data were analyzed using SPSS version 22.0. **Results:** The mean age of the patients was 61.1±12.1 years. Similarly, the mean height, weight and body mass index (BMI) was 71.6±11.4 kg, 166.2±9.7 cm and 26.1±4.7 kg/m² respectively. Family history of DM was positive in 30.6% patients while family history of obesity was positive in 23.8% individuals. The DM was prevalent in 31.3% HCV patients in which 58% were newly diagnosed. Statistical significant association was observed in HCV obese patient than non-obese patients with DM (p-value 0.03). Furthermore, obese patients were 12.4 times more likely to develop DM as compared to non-obese patients (OR, 95%CI 12.4 (5.52-28.5)). **Conclusion:** DM is more common in HCV patients particularly if the patient is obese. It is necessary to screen and control earlier for the presence of type 2 diabetes mellitus and also to rule out HCV infection among diabetic populations which is rarely done on population-based studies.

Keywords: Hepatitis C virus, Diabetes mellitus, Body mass index, World health Organization

Introduction

Hepatitis C virus (HCV) causes inflammation of the Liver and is a single-stranded RNA virus of the family flaviviridae; it is one of the major cause of life-threatening chronic liver disease, with global prevalence estimated 177.5 million HCV infected adults (101). Some studies reveals the risk for diabetes to be 10.9% for anti-HCV seronegative and 16.7% for anti-HCV seropositive respectively and the treatment of HCV infection have been reported to decrease the episodes of hyperglycemia (102, 103). In East

and South Asia the prevalence of hepatitis C is highest, with the key factors being the family history of diabetes and sedentary life style that contribute to development of diabetes mellitus which lead to the development of micro-vascular complications of neuropathy, nephropathy and retinopathy (104).

CORRESPONDENCE AUTHOR

Dr Nizamuddin

Department of Pharmacology
Khyber Medical College, Peshawar
Drnizam99@yahoo.com

Diabetes is a metabolic disorder of functional insulin deficiency. The top countries of highest diabetes prevalence are United States (U.S), China and India (105). In Pakistan diabetes mellitus prevalence is up to 26.3% with 14.4% as pre-diabetes (106). Studies have shown that diabetes prevalence (36%) is more in patients with Hepatitis C virus (HCV) infections (107). The acceleration of the course of chronic hepatitis C and the decreased response to antiviral therapy may be attributed to insulin resistance. The developing countries have reported higher prevalence of chronic liver disease due to hepatitis C reporting (22%), (4.8%), (3.2%) for Egypt, Pakistan and China respectively (108). The processes through which HCV is associated with Type 2 DM include direct viral effects, insulin resistance, chemokine, cytokine signal suppression and other immune mediated mechanisms (109). HCV patients have higher reports of T2DM occurrence, portraying a relationship between T2DM and HCV infection. The subpar therapeutic response, aggravated liver fibrosis, insulin resistance and deteriorating liver condition are attributed to the comorbidity of T2DM with HCV infection (110).

Pakistan is enduring an HCV epidemic of historical proportions, with approximately one in every 20 Pakistanis being infected, having high prevalence in all-risk populations, HCV has major role in liver disease burden in this country (111). According to the projections by WHO, diabetes will be the 7th leading cause of death by 2030 and this have become a problem in Pakistan with 7.1 million diabetics in 2010 and expected 13.8 million diabetics till 2030 (108). Our rationale was to find the distribution of diabetes in HCV patients and correlate it with age, gender, body mass

index (BMI) and history of duration of diabetes.

Methods

This descriptive cross sectional study was conducted from 27th October 2020 till 26th April 2021 at Medicine Unit, Khyber Teaching Hospital (KTH) Peshawar and KMC Peshawar. A total of 160-sample size was calculated using WHO calculator based on prevalence of 28.3% with the margin of error 5% and confidence interval of 95%. After Ethical approval from KMC via letter no. KMC/EB02/010, HCV patients of either gender, willing to participate were enrolled in the study. The demographic data was recorded on pre-designed proforma after detailed interview and then 5cc blood was taken from each patient for RBS and HbA1C determination. Patients not willing to participate in the study, patients with hepatitis B infection as per ELIZA results and patients with history of type 1 DM were excluded from the study.

SPSS version 22 was used for analysis. Frequency, percentages and Mean \pm SD of quantitative variables were calculated. Stratification of effect modifiers factors like age, gender, BMI, family history of diabetes, family history of obesity was presented against the status of type II diabetes and Chi-square test was applied with the p-value of ≤ 0.05 being as statistically significant. Odds ratio with 95% confidence interval was calculated to determine the future risk. All the selected statistical values were two tailed.

Results

The mean age of the patients was 61.1 ± 12.1 years. Similarly, the mean height, weight and body mass index (BMI) was 166.2 ± 9.7 cm, 71.6 ± 11.4 kg and 26.1 ± 4.7 kg/m² respectively. The mean random blood sugar (RBS) among diabetic patients was 265 ± 23.8 mg/dl. The details are shown in table 1.

Similarly, male participants were 53.8% while female were 46.3%. Family history of DM was positive in 30.6% patients while family history of obesity was positive in 23.8% individuals. The DM was prevalent in 31.3% HCV patients in which 58% were newly diagnosed as shown in Figure 1. The results are summarized in Table 2.

Distribution of Diabetes in HCV patients




Figure 1: Distribution of diabetes in HCV patients.

Table 1: Demographics of study participants

Variable	Mean	Standard deviation
Age (years)	61	12.1
Weight (Kg)	71.6	11.4
Height (cm)	166.2	9.7
BMI (kg/m ²)	26.1	4.7
Random Blood sugar (RBS) (mg/dl)	295	23.8

Table 2: Characteristics of study population

Parameter	Sub-Types	Frequency (%)
Gender	Male	86 (53.8)
	Female	74 (46.3)
Diabetes	-	50 (31.3)
Type of diabetes	Old	21 (42)
	New onset	29 (58)
Family history of diabetes	-	49 (30.6)
Family history of obesity	-	38 (23.8)

To find the possible association between different study parameters with DM, chi-square test was applied. The results reveal that no statistical significant association between different age groups and gender with DM. However, Females are 1.75 times more likely to develop diabetes as compare to males with OR, 95%CI 1.73, 0.89-3.43. Obesity was significantly associated with DM with p value 0.03. Furthermore, obese patients were 12.4 times more prone to develop diabetes as compared to normal BMI patients with OR, 95%CI 12.4, 5.52-28.5. All the results are given in table 3 while the significant association of BMI and DM is shown in Figure 2.

Table 3: Association of different study parameters with diabetes mellitus

Parameters		Status of diabetes		P-Value	OR (95%CI)
		Yes	No		
Age groups	40-60 years	24	50	0.86	0.9 (0.47-1.73)
	61-80 years	26	60		
Gender	Male	22	64	0.12	1.75 (0.89-3.43)
	Female	28	46		
BMI	Normal	29	83	0.03	12.4 (5.52-28.5)
	Obese	39	09		

BMI-Body mass index




Figure 2: Association of BMI with DM

Discussion

Extra hepatic manifestations have been identified in HCV infection, yet it remains to be understood whether HCV infection leads to diabetes or vice versa, but it is still discussed that diabetics have higher risk of exposure to HCV infections. It has been established that HCV infected patients increased frequency of glucose intolerance and some studies indicate that HCV infections may be an additional risk factor for development of diabetes (112). In our study, there were 86 (53.8%) were males while 74 (46.3%) were females which is also reported in a 2024 study with higher frequency of males.(113) According to a recent study published in 2020 by Kadla et al shows a bit higher percentage of females are compared to males (114).

Our study revealed a total of 31.3% patients having type II diabetes with chronic hepatitis C infection. In consistent with our findings a southeast Asian study conducted in 2013 also reported 31.5% of prevalence of diabetes in HCV infected patients and observed that cirrhotic patients appeared significantly more likely (p-value 0.01) to be diabetic as compared with non-cirrhotic patients (115). Among these 31.3% DM patients, 42% were

old diabetes while 58% were new onset of diabetics. A similar prevalence of new and old DM cases were also reported by the Studies in the past where the prevalence of new and old onset of DM in HCV is 36% and 28.3% patients respectively (107, 116). Another study also found that patients with HCV infections are 2 folds more prone to develop diabetes as compared non-HCV patients (114). The HCV plays important role in the development and pathogenesis of DM. The viral proteins causes insulin resistance (IR) and oxidative stress at cellular level by producing reactive oxygen species (117, 118) . Furthermore, these proteins also causes phosphorylation of insulin receptor leading to IR thus leading to the development of DM in such patients (114, 119). Obesity is one of the most significant factors for the development of DM (120, 121). In our study, obesity was positive in 39 (23.3%) DM patients. The level of significance was high (p-value 0.03) when compare patient with normal BMI and obese in relation to DM. Furthermore, obese individuals were 12.4 times more likely to develop DM as compared to non-obese individuals. According to the nationwide diabetes report of national program for prevention and control of DM (NPPCD-2021), obesity was found as an independent risk for development of DM. Furthermore, obese individuals develops diabetic complications more early as compared to non-obese individuals (122, 123). Thus treating HCV in patients with DM and obesity will further complicates the treatment regimen and will results in bad prognosis of the patients.

Conclusion

Our study concludes that type 2 diabetes is very common in patients with hepatitis C infection. Detection of HCV infections among diabetic patients is rarely ruled out in

population-based studies, hence screening and early control is necessary for HCV infected diabetic patients.

Conflict of Interest: Authors declare no conflict of interest.

Funding: No funding was received for this project

References

1. Devinsky O, Vezzani A, O'Brien TJ, Jette N, Scheffer IE, de Curtis M, et al. Epilepsy. *Nat Rev Dis Primers*. 2018; 4:18024.
2. Peek SI, Twele F, Meller S, Packer RMA, Volk HA. Epilepsy is more than a simple seizure disorder: Causal relationships between epilepsy and its co morbidities. *The Veterinary Journal*. 2024; 303:106061.
3. Parsons ALM, Bucknor EMV, Castroflorio E, Soares TR, Oliver PL, Rial D. The Interconnected Mechanisms of Oxidative Stress and Neuroinflammation in Epilepsy. *Antioxidants*. 2022;11(1):157.
4. Frantseva MV, Perez Velazquez JL, Tsoraklidis G, Mendonca AJ, Adamchik Y, Mills LR, et al. Oxidative stress is involved in seizure-induced neurodegeneration in the kindling model of epilepsy. *Neuroscience*. 2000;97(3):431-5.
5. Vezzani A, Dingledine R, Rossetti AO. Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application. *Expert review of neurotherapeutics*. 2015;15(9):1081-92.
6. Rowley S, Patel M. Mitochondrial involvement and oxidative stress in temporal lobe epilepsy. *Free Radical Biology and Medicine*. 2013;62:121-31.
7. Hassanzadeh P, Arbabi E, Atyabi F, Dinarvand R. Ferulic acid exhibits antiepileptogenic effect and prevents oxidative stress and cognitive impairment in the kindling model of epilepsy. *Life Sciences*. 2017;179:9-14.
8. Waldbaum S, Patel M. Mitochondrial dysfunction and oxidative stress: a contributing link to acquired epilepsy? *Journal of bioenergetics and biomembranes*. 2010;42:449-55.
9. Shekh-Ahmad T, Kovac S, Abramov A, Walker M. Reactive oxygen species in status epilepticus. *Epilepsy & behavior*. 2019; 101:106410.
10. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. *Journal of ethnopharmacology*. 2005;100(1-2):72-9.
11. Kumar KH, Tamatam A, Pal A, Khanum F. Neuroprotective effects of *Cyperus rotundus* on SIN-1 induced nitric oxide generation and protein nitration: ameliorative effect against apoptosis mediated neuronal cell damage. *Neurotoxicology*. 2013 ; 34:150-9.
12. Shim JS, Kim HG, Ju MS, Choi JG, Jeong SY, Oh MS. Effects of the hook of *Uncaria rhynchophylla* on neurotoxicity in the 6-hydroxydopamine model of Parkinson's disease. *Journal of Ethnopharmacology*. 2009; 126(2):361-5.
13. El Omri A, Han J, Yamada P, Kawada K, Abdrabbah MB, Isoda H. Rosmarinus officinalis polyphenols activate cholinergic activities in PC12 cells through phosphorylation of ERK1/2. *Journal of ethnopharmacology*. 2010; 131(2):451-8.
14. Sasaki K, El Omri A, Kondo S, Han J, Isoda H. Rosmarinus officinalis polyphenols produce anti-depressant like effect through monoaminergic and cholinergic functions modulation. *Behavioural Brain Research*. 2013; 238:86-94.
15. Lo W-Y, Tsai F-J, Liu C-H, Tang N-Y, Su S-Y, Lin S-Z, et al. *Uncaria rhynchophylla*

- upregulates the expression of MIF and cyclophilin A in kainic acid-induced epilepsy rats: a proteomic analysis. *The American journal of Chinese medicine*. 2010; 38(04):745-59.
16. Carro-Juárez M, Rodríguez-Landa JF, de Lourdes Rodríguez-Peña M, de Jesús Roviroso-Hernández M, García-Orduña F. The aqueous crude extract of *Montanoa frutescens* produces anxiolytic-like effects similarly to diazepam in Wistar rats: involvement of GABAA receptor. *Journal of Ethnopharmacology*. 2012;143(2):592-8.
 17. Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. *The American journal of clinical nutrition*. 2008; 88(1):38-50.
 18. Kardum N, Takić M, Šavikin K, Zec M, Zdunić G, Spasić S, et al. Effects of polyphenol-rich chokeberry juice on cellular antioxidant enzymes and membrane lipid status in healthy women. *Journal of Functional Foods*. 2014; 9:89-97.
 19. Arts IC, Hollman PC. Polyphenols and disease risk in epidemiologic studies. *The American journal of clinical nutrition*. 2005; 81(1):317S-25S.
 20. Barkatullah B, Ibrar M. Plants profile of malakand pass hills, district malakand, Pakistan. *African Journal of Biotechnology*. 2011;10(73):16521-35.
 21. Sharma B, Singh B, Dhyan D, Verma PK, Karthigeyan S. Fatty acid composition of wild growing rose species. *J Med Plants Res*. 2012;6:1046-9.
 22. Honarvar M, Javidnia K, Khosh-Khui M. Essential oil composition of fresh and dried flowers of *Rosa moschata* from Iran. *Chemistry of Natural Compounds*. 2011;47:826-8.
 23. Ali N, Alam H, Khan A, Ahmed G, Shah WA, Nabi M, et al. Antispasmodic and antidiarrhoeal activity of the fruit of *Rosa moschata* (J). *BMC Complement Altern Med*. 2014;14:485.
 24. Hossain MA, Weli AM, Ahmed SHI. Comparison of total phenols, flavonoids and antioxidant activity of various crude extracts of *Hyoscyamus gallagheri* traditionally used for the treatment of epilepsy. *Clinical Phytoscience*. 2019;5(1):20.
 25. Kültür Ş. Medicinal plants used in Kırklareli Province (Turkey). *Journal of Ethnopharmacology*. 2007;111(2):341-64.
 26. Nazir N, Khalil AAK, Nisar M, Zahoor M, Ahmad S. HPLC-UV characterization, anticholinesterase, and free radical-scavenging activities of *Rosa moschata* Herrm. leaves and fruits methanolic extracts. *Brazilian Journal of Botany*. 2020;43:523-30.
 27. Kumar N, Bhandari P, Singh B, Bari SS. Antioxidant activity and ultra-performance LC-electrospray ionization-quadrupole time-of-flight mass spectrometry for phenolics-based fingerprinting of Rose species: *Rosa damascena*, *Rosa bourboniana* and *Rosa brunonii*. *Food and Chemical Toxicology*. 2009;47(2):361-7.
 28. Shashni S, Sharma S. Antioxidant activities of dried wild rosehips (*Rosa moschata*) of Kullu Valley, Northwestern Indian Himalaya. *Indian Journal of Natural Products and Resources (IJNPR)[Formerly Natural Product Radiance (NPR)]*. 2022;13(3):339-45.
 29. Ayati Z, Amiri MS, Ramezani M, Delshad E, Sahebkar A, Emami SA. Phytochemistry, traditional uses and pharmacological profile of rose hip: A

- review. *Current pharmaceutical design*. 2018;24(35):4101-24.
30. Sapkota B, Devkota HP, Poudel A, Poudel P, Thapa R. Chapter 35 - Rosa spp. (Rosa canina L., R. macrophylla Lindl., R. moschata Herrm., R. multiflora Thunb.). In: Belwal T, Bhatt I, Devkota H, editors. *Himalayan Fruits and Berries: Academic Press*; 2023. p. 371-81.
 31. Ouerghemmi S, Sebei H, Siracusa L, Ruberto G, Saija A, Cimino F, et al. Comparative study of phenolic composition and antioxidant activity of leaf extracts from three wild Rosa species grown in different Tunisia regions: Rosa canina L., Rosa moschata Herrm. and Rosa sempervirens L. *Industrial Crops and Products*. 2016;94:167-77.
 32. Ali N, Alam H, Khan A, Ahmed G, Shah WA, Nabi M, et al. Antispasmodic and antidiarrhoeal activity of the fruit of Rosa moschata (J). *BMC complementary and alternative medicine*. 2014;14(1):1-6.
 33. Jamal M, ur Rehman M, Nabi M, Awan AA, Ali N, Sherkheli MA, et al. Evaluation of safety profile and stress suppressant activity of Rosa moschata in mice. *Pak J Pharm Sci*. 2019;32(6):2659-65.
 34. Bhandary SK, Bhat VS, Sharmila K, Bekal MP. Preliminary phytochemical screening of various extracts of Punica granatum peel, whole fruit and seeds. *Journal of Health and Allied Sciences NU*. 2012;2(04):34-8.
 35. Shimada T, Yamagata K. Pentylene-tetrazole-Induced Kindling Mouse Model. *Journal of visualized experiments : JoVE*. 2018(136).
 36. Van Erum J, Van Dam D, De Deyn PP. PTZ-induced seizures in mice require a revised Racine scale. *Epilepsy & behavior* : E&B. 2019;95:51-5.
 37. Van Erum J, Van Dam D, De Deyn PP. PTZ-induced seizures in mice require a revised Racine scale. *Epilepsy & Behavior*. 2019;95:51-5.
 38. Kraeuter A-K, Guest PC, Sarnyai Z. The Y-maze for assessment of spatial working and reference memory in mice. *Pre-clinical models: Springer*; 2019. p. 105-11.
 39. Zakria M, Ahmad N, Al Kury LT, Alattar A, Uddin Z, Siraj S, et al. Melatonin rescues the mice brain against cisplatin-induced neurodegeneration, an insight into antioxidant and anti-inflammatory effects. *Neurotoxicology*. 2021;87:1-10.
 40. Draper HH, Hadley M. [43] Malondialdehyde determination as index of lipid Peroxidation. *Methods in enzymology*. 186: Elsevier; 1990. p. 421-31.
 41. Pires LF, Costa LM, de Almeida AAC, Silva OA, Cerqueira GS, de Sousa DP, et al. Is there a correlation between in vitro antioxidant potential and in vivo effect of carvacryl acetate against oxidative stress in mice hippocampus? *Neurochemical research*. 2014;39(4):758-69.
 42. Ellman GL. Tissue sulfhydryl groups. *Archives of biochemistry and biophysics*. 1959;82(1):70-7.
 43. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. *The Journal of laboratory and clinical medicine*. 1963;61:882-8.
 44. Czczot H, Scibior D, Skrzycki M, Podsiad M. Glutathione and GSH-dependent enzymes in patients with liver cirrhosis and hepatocellular carcinoma. *Acta biochimica Polonica*. 2006;53(1):237-42.
 45. Nelson DP, Kiesow LA. Enthalpy of decomposition of hydrogen peroxide by catalase at 25 degrees C (with molar extinction coefficients of H₂O₂ solutions

- in the UV). *Analytical biochemistry*. 1972;49(2):474-8.
46. Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2- $\Delta\Delta$ CT Method. *Methods*. 2001;25(4):402-8.
 47. Obay BD, Taşdemir E, Tümer C, Bilgin HM, Atmaca M. Dose dependent effects of ghrelin on pentylentetrazole-induced oxidative stress in a rat seizure model. *Peptides*. 2008;29(3):448-55.
 48. Khatami P, Mirazi N, Khosravi M, Bananej M. Anticonvulsant activity of oxaprozol in a rat model of pentylentetrazole-induced seizure by targeting oxidative stress and SIRT1/PGC1 α signaling. *Canadian Journal of Physiology and Pharmacology*. 2022.
 49. Hoyos CM, Stephen C, Turner A, Ireland C, Naismith SL, Duffy SL. Brain oxidative stress and cognitive function in older adults with diabetes and pre-diabetes who are at risk for dementia. *Diabetes Research and Clinical Practice*. 2022;184:109178.
 50. Ren Y, Sun-Waterhouse D, Ouyang F, Tan X, Li D, Xu L, et al. Apple phenolic extracts ameliorate lead-induced cognitive impairment and depression-and anxiety-like behavior in mice by abating oxidative stress, inflammation and apoptosis via the miR-22-3p/SIRT1 axis. *Food & Function*. 2022;13(5):2647-61.
 51. Seigers R, Fardell JE. Neurobiological basis of chemotherapy-induced cognitive impairment: A review of rodent research. *Neuroscience & Biobehavioral Reviews*. 2011;35(3):729-41.
 52. Jahanbani R, Bahramnejad E, Rahimi N, Shafaroodi H, Sheibani N, Moosavi-Movahedi AA, et al. Anti-seizure effects of walnut peptides in mouse models of induced seizure: The involvement of GABA and nitric oxide pathways. *Epilepsy Research*. 2021;176:106727.
 53. Scheuer T, Endesfelder S, auf dem Brinke E, Bühner C, Schmitz T. Neonatal Oxidative Stress Impairs Cortical Synapse Formation and GABA Homeostasis in Parvalbumin-Expressing Interneurons. *Oxidative Medicine and Cellular Longevity*. 2022;2022:8469756.
 54. Tu J, Jin Y, Zhuo J, Cao X, Liu G, Du H, et al. Exogenous GABA improves the antioxidant and anti-aging ability of silkworm (*Bombyx mori*). *Food Chemistry*. 2022;383:132400.
 55. Alharbi KS. Anticonvulsant effects of desvenlafaxine on modulating brain monoamine and oxidative stress in mice. *Brazilian Journal of Biology*. 2021;83.
 56. Mohamed HM, Mahmoud AM. Chronic exposure to the opioid tramadol induces oxidative damage, inflammation and apoptosis, and alters cerebral monoamine neurotransmitters in rats. *Biomedicine & Pharmacotherapy*. 2019;110:239-47.
 57. Abou Seif HS. Physiological changes due to hepatotoxicity and the protective role of some medicinal plants. *Beni-Suef University Journal of Basic and Applied Sciences*. 2016;5(2):134-46.
 58. Ali N, Alam H, Khan A, Ahmed G, Shah WA, Nabi M, et al. Antispasmodic and antidiarrhoeal activity of the fruit of *Rosa moschata* (J). *BMC Complement Altern Med*. 2014;14:485-.

HISTORY	
Date received:	05-08-2024
Date sent for review:	06-08-2024
Date received reviewers comments:	13-08-2024
Date received revised manuscript:	23-08-2022
Date accepted:	26-08-2024

CONTRIBUTION OF AUTHORS	
AUTHOR	CONTRIBUTION
Baghdad Khan	A,B,C
Waqar Ahmad	B,C
Fahad Naim	A,C
Nizamuddin	A,B,C
Husnain Qadir	B,C
Samiullah	A,B

KEY FOR CONTRIBUTION OF AUTHORS:

- A. Conception/Study/Designing/Planning
- B. Active Participation in Active Methodology
- C. Interpretation/ Analysis and Discussion